⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
APLLTD - Swing Trade Analysis with AI Signals
Last Updated Time : 05 Nov 25, 7:43 am
Back to Swing Trade List✅ Swing Trade Rating: 3.7
Entry Zone: ₹940–₹955 (only if MACD flattens and RSI stays below 65)
Exit if held: ₹1,020–₹1,050 (near resistance and prior breakout zone)
📊 Technical & Fundamental Snapshot
- 📈 Current Price: ₹961
- 📈 52W High/Low: ₹1,153 / ₹725
- 📈 RSI: 62.3 (approaching overbought)
- 📉 MACD: -3.20 (bearish divergence)
- 📈 Volume: 16.6L vs 1W Avg 4.86L (strong surge)
- 📈 FII/DII Holding Change: +0.08% / -0.16%
- 📈 P/E: 42.5 vs Industry 33.1 (premium valuation)
- 📉 PEG Ratio: -12.9 (not meaningful due to earnings base)
✅ Positive
- 📈 ROCE & ROE: 11.3% and 9.68% — improving capital efficiency.
- 📈 EPS: ₹22.6 — solid earnings base.
- 📈 Volume Spike: Indicates strong institutional interest post Q2 results.
- 📈 Above DMA 50 & 200: Price sustaining above key averages.
- 📈 Dividend Yield: 1.14% — modest passive income.
⚠️ Limitation
- 📉 MACD Negative: Bearish divergence despite price strength.
- 📉 RSI > 60: Approaching overbought — caution for fresh entry.
- 📉 PEG Ratio: Negative — not a reliable growth valuation metric currently.
- 📉 DII Exit: Domestic institutions trimmed stake slightly.
🚨 Company Negative News
- 📉 India Branded Business: Slower growth at 5% YoY — lagging peers in domestic formulations.
- 📉 Valuation Risk: P/E at 42.5 — premium vs sector average.
📈 Company Positive News
- 🚀 Q2FY26 PAT: ₹185 Cr — up 21% YoY; revenue ₹1,910 Cr, up 16% YoY.
- 📈 US Generics: Revenue up 21% YoY to ₹566 Cr with 3 new launches.
- 📦 Ex-US International: Revenue up 31% YoY to ₹392 Cr — strong diversification.
- 📈 EBITDA Margin: Expanded to 16.5% from 14.5% YoY — operational efficiency improving.
💊 Industry
- 📈 Global Pharma Demand: US and emerging markets driving generic volumes.
- 📉 Pricing Pressure: US generics still face competitive intensity and regulatory hurdles.
🧾 Conclusion
- ✅ Technically viable swing setup with strong volume and earnings momentum.
- 📥 Entry near ₹940–₹955 if MACD flattens and RSI stays below 65.
- 📤 Exit near ₹1,020–₹1,050 (resistance and prior breakout zone).
- 📈 Fundamentals improving, momentum building — suitable for alert-driven tactical trades with basket overlay.
Sources
CNBC TV18 – Q2 Results
Business Standard – PAT Growth
ScanX – Earnings Summary
Back to Swing Trade ListNIFTY 50 - Today Top Swing Trade Stock Picks
NEXT 50 - Today Top Swing Trade Stock Picks
MIDCAP - Today Top Swing Trade Stock Picks
SMALLCAP - Today Top Swing Trade Stock Picks